Amy Valley: Weighing the Pros and Cons of Artificial Intelligence in Oncology Practices
Amy Valley, vice president for clinical strategy and technology solutions at Cardinal Health, weighs both the benefits and potential risks of physicians using artificial intelligence technology in their oncology practices.
COA's Nicolas Ferreyros on the Senate PBM Hearing and the FTC Investigation
Nicolas Ferreyros, managing director at Community Oncology Alliance (COA), discusses the recent Senate commerce hearing on pharmacy benefit managers (PBMs), which brought bipartisan attention and energy towards addressing the concerns related to PBMs in Washington.
Disparities Exist in Patient Selection for ECMO, Study Finds
A study including data from more than 2 million patients highlights gender, health insurance, and income disparities in patients receiving extracorporeal membrane oxygenation (ECMO) while hospitalized for severe respiratory illness.
Dr Davey Daniel on the Importance of Biomarker Tests for Patients With Lung Cancer
Biomarker testing is a key tool in lung cancer treatment, and Kentucky recently passed a law requiring payers to cover biomarker tests with the intention to address high rates of lung cancer in the state.
Dr Debra Patt: Consolidation and New Advanced Therapies in Oncology
Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, discusses financial drivers affecting community oncology as well as new advances within cancer care that allow it to be treated as a chronic disease.
Nicolas Ferreyros: There Is Growing Recognition the 340B Program Is "Out of Control"
Growing bipartisan awareness of issues with the 340B drug pricing program will hopefully lead to reform, says Nicolas Ferreyros, BA, managing director of policy, advocacy, and communications at the Community Oncology Alliance.